PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]
Read More
Report: New blood test for early detection of 8 major cancer types What does this mean for you? You may have heard the recent hype about a new study in which a blood test was used for the early detection of 8 major cancer types. What does the study really mean and, more importantly, when […]
Read MoreA study published in Lancet Oncology by Dr. Iain McNeish (2016 Rivkin Pilot Award Recipient), Dr. Elizabeth Swisher (2009 Rivkin Pilot Award Recipient), and colleagues provided key data that helped fuel the FDA’s recent approval of rucaparib for ovarian cancers with defects in the BRCA1 and BRCA2 genes in women previously treated with two or more chemotherapies.
Read More
This week, the Rivkin Center extended a special invitation to a very select group of ovarian cancer researchers to apply for a major new Rivkin research grant. This is a big departure from our typical funding model.
Read More